IOVA vs. ATAI

In the year-to-date period, IOVA achieves a -9.23% return, which is significantly higher than ATAI's -15.60% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and Atai Life Sciences N.V. (ATAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current IOVA Sharpe Ratio is 0.03, which is higher than the ATAI Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of IOVA and ATAI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither IOVA nor ATAI has paid dividends to shareholders.

The maximum IOVA drawdown since its inception was -99.37%, roughly equal to the maximum ATAI drawdown of -94.77%. Use the drawdown chart below to compare losses from any high point for IOVA and ATAI. For additional features, visit the drawdowns tool.

The current volatility for Iovance Biotherapeutics, Inc. (IOVA) is 17.60%, while Atai Life Sciences N.V. (ATAI) has a volatility of 19.61%. This indicates that IOVA experiences smaller price fluctuations and is considered to be less risky than ATAI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Iovance Biotherapeutics, Inc. and Atai Life Sciences N.V.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.